IQVIA Q4 Earnings & Revenues Beat Estimates, Increase Y/Y

IQVIA Holdings Analytics Inc. IQV has reported impressive fourth-quarter 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate.

Adjusted earnings were $3.42 per share, surpassing the Zacks Consensus Estimate by a slight margin and gaining 9.6% on a year-over-year basis. Total revenues of $4.4 billion beat the consensus estimate by 2.8% and rose 10.3% from the year-ago quarter.

IQV stock lost 1.4% in a year compared with the industry’s 10.9% dip. However, the Zacks S&P 500 Composite rose 17.8% during the same period.

IQVIA’s Strong Segmental Growth in Q4

The Research and Development segment’s revenues were $2.3 billion. It rose 9.9% from the year-ago quarter and 8.2% on a constant-currency basis and met the Zacks Consensus Estimate.

IQV generated $1.8 billion in revenues from the Technology and Analytics segment. The metric increased 9.8% year over year and 7.1% on a constant-currency basis, standing at par with the consensus estimate.

Contract Sales and Medical Solutions revenues increased 18.6% on a year-over-year basis to $210 million. It moved up 15.3% on a constant-currency basis. Revenues surpassed the consensus mark of $193.2 million.

IQV’s Robust Profitability & Solid Cash Flow

Adjusted EBITDA for the fourth quarter of 2025 was $1 billion, a 5% rise from the year-ago quarter.

The company exited the quarter with cash and cash equivalents of $2 billion compared with $1.8 billion in the preceding quarter. Long-term debt (less current portion) was $13.9 billion compared with $15 billion at the end of the third quarter of 2025.

Net cash generated from operating activities was $735 million and capital expenditure came in at $174 million. During the fourth quarter of 2025, IQV reported $561 million in free cash flow.

IQV’s 2026 Outlook

For 2026, IQVIA’s revenue outlook comes in at $17.15-$17.35 billion. The guided range is higher than the Zacks Consensus Estimate of $17.03 billion.

For EPS, management expects it to be within a range of $12.55-$12.85. The outlook is lower than the consensus estimate of $12.93. IQVIA’s adjusted EBITDA view is kept at $3.98-$4.03 billion.

IQV carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Earnings Snapshot

Equifax Inc. EFX has reported impressive fourth-quarter 2025 results.

EFX posted $2.09 in EPS, beating the Zacks Consensus Estimate by 2.2%. This marked a 1.4% dip from the fourth quarter of 2025. The company recorded $1.6 billion in its top line, surpassing the consensus estimate by 1.3%. Revenues spiked 9.1% from the year-ago quarter’s actual.

Gartner, Inc. IT has reported fourth-quarter 2025 results.

The company’s adjusted earnings per share of $3.94 beat the Zacks Consensus Estimate by 12.6% but decreased 27.7% from the year-ago quarter. Revenues of $1.8 billion beat the consensus estimate by a slight margin and improved 2.2% year over year.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research